Answers are grounded in this paper and cite their sources.
Evaluation shows MCP-1 levels correlate with glycemic control and PAD in type 2 diabetes with metabolic syndrome, implying a potential role in disease progression.
We evaluated the serum levels of monocyte chemoattractant protein 1 (MCP-1) and their association with peripheral arterial disease (PAD) in 199 patients with type 2 diabetes mellitus (T2DM) and metabolic syndrome ([MetS], group A) in comparison with 109 healthy controls (group B). In group A, MCP-1 levels were significantly (P < .001) higher than group B and exhibited a positive correlation with HbA1c (P < .001) and a negative correlation with ankle-brachial index (P < .001). In the same group, patients with PAD had significantly higher MCP-1 levels compared with those without PAD (P < .001). In conclusion, T2DM patients with MetS exhibit higher serum MCP-1 levels. The latter is associated with worse glycemic control and PAD. These results suggest a potential contributory role for MCP-1 in the pathogenesis of PAD in the presence of hyperglycemia and MetS in T2DM.
No takes yet. Share an insight, caveat, or question.
Papatheodorou et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: